NXPL · NextPlat Corp

NextPlat’s Q1 2026 results reflect a deliberate operational pivot under its ongoing turnaround initiative: while top-line revenue declined 29% year-over-year to $9.9 million—primarily driven by a $4.7 million drop in healthcare pharmacy prescription revenue due to Medicare reimbursement rate reductions and payer mix shifts—the Company significantly improved profitability levers. Gross margin surged to 35%, a record high, fueled by the strategic shift toward higher-margin contracted medication fulfillment services (up 36% year-over-year to $1.9 million) and favorable cost impacts from the January 2026 launch of the Medicare Maximum Fair Price program. Healthcare segment gross margin nearly doubled to 39%, underscoring the efficacy of this mix shift. Concurrently, operating expenses fell 9% to $4.5 million, aided by headcount rationalization and reduced executive compensation, enabling a 42% reduction in net loss to $1.1 million. Management explicitly tied these improvements to disciplined cost control and enhanced business development—evidenced by five new 340B entity contracts secured in Q1—and reaffirmed expectations for positive operating income in the latter half of 2026. The balance sheet remains strong with $11.0 million in cash and no unsecured debt, though receivables collection timing created a near-term working capital drag. Forward-looking commentary emphasizes continued expansion of nationwide pharmacy fulfillment capabilities and growth in government/military IoT hardware sales via its GTC subsidiary, positioning the Company to leverage its improved margin structure and leaner cost base for sustainable profitability later in the year.